MedTrace Logo

Respiratory Control and Narcotic Effects

NCT04047550 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2020-08-27

No results posted yet for this study

Summary

The aim of this study is to provide data that will assess the role of ventilatory chemosensitivity (respiratory drive) in determining postoperative respiratory depression due to opioids. In a group of patients requiring surgery and admission to hospital, before surgery, ventilatory chemosensitivity will be assessed in the presence or absence of an infusion of remifentanil. Parameters will be correlated with ventilatory depression events after surgery. A secondary aim is to determine whether respiratory depression is more likely during specific phases of sleep.

Conditions

  • Ventilatory Depression
  • Opioid Intoxication
  • Opioid Toxicity

Interventions

DIAGNOSTIC_TEST

Ventilatory chemosensitivity

Using this technique, the patient first voluntarily hyperventilates to a PETCO2 value of 20-25 mmHg, then undergoes a rebreathing test allowing the PCO2 to rise to 55-60 mmHg while PETO2 is maintained at 150 mmHg. The procedure is then repeated with PETO2 clamped at 50 mmHg. Parameters derived from this method include slopes of the ventilatory response during hyperoxia and hypoxia.

Sponsors & Collaborators

Principal Investigators

  • Richard E Moon, MD · Duke University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-08
Primary Completion
2019-02-09
Completion
2019-02-09
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04047550 on ClinicalTrials.gov